Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype.
Massimino M, Barretta F, Dossena C, Minasi S, Buttarelli FR, Biassoni V, Oriani M, Schiavello E, Ficorilli M, Nigro O, Pollo B, Antonelli M, Donofrio V, Maggioni M, Kool M, Pecori E, Vennarini S, Giangaspero F, Gianno F, Erbetta A, Chiapparini L, Luksch R, Barzanò E, Meazza C, Podda M, Spreafico F, Terenziani M, Bergamaschi L, Ferrari A, Casanova M, Chiaravalli S, Gattuso G, Modena P, Bailey S, De Cecco L.
Massimino M, et al.
Neuro Oncol. 2025 Jan 12;27(1):209-218. doi: 10.1093/neuonc/noae189.
Neuro Oncol. 2025.
PMID: 39331528
Free PMC article.
BACKGROUND: We applied the strategy for M+ medulloblastoma across all high-risk subgroups, including LC/A histology, TP53 mutations, and MYC/MYCN amplification. ...Boosts to posterior fossa/residual metastatic(M+) deposits were given up to a total dose of 60 Gy/9 Gy …
BACKGROUND: We applied the strategy for M+ medulloblastoma across all high-risk subgroups, including LC/A histology, TP53 mutations, …